Julien Edeline

机构：Inserm, Université Rennes 2, Oncogenesis Stress Signaling, Centre Eugène Marquis, Université de Rennes · ORCID：0000-0002-8289-7741

发表论文 412 篇 · 总被引 18725 次 · h-index 53

代表论文

• Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial (2026 · ˜The œLancet. Gastroenterology & hepatology · 被引 1)
• Effectiveness and safety of selective internal radiation therapy using yttrium-90 glass microspheres for hepatocellular carcinoma: real-world results from the multi-center prospective PROACTIF cohort of 989 patients (2026 · EClinicalMedicine · 被引 1)
• Prognostic Impact of Concomitant Genomic Alterations in FGFR2 ‐Positive Cholangiocarcinoma Treated With Pemigatinib (2026 · Liver International)
• Integrating systemic therapy in the earlier stages of liver cancer (2026 · Journal of Hepatology)
• Adjuvant capecitabine in resected biliary tract cancer: a real-world data from the BILCAP-Real study (ACABi multicentre cohort) (2026 · JHEP Reports)
• Antiangiogenic therapies in gastric cancer: future directions for 2026 and beyond: an UNICANCER gastrointestinal group (UCGI) perspective (2026 · Cancer Treatment Reviews)